Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG. Sasi BK, et al. Among authors: priebe v. Leukemia. 2019 Oct;33(10):2416-2428. doi: 10.1038/s41375-019-0442-8. Epub 2019 Mar 14. Leukemia. 2019. PMID: 30872780
The transcription factor ETS1 in lymphomas: friend or foe?
Testoni M, Chung EY, Priebe V, Bertoni F. Testoni M, et al. Among authors: priebe v. Leuk Lymphoma. 2015 Jul;56(7):1975-80. doi: 10.3109/10428194.2014.981670. Epub 2015 Jan 14. Leuk Lymphoma. 2015. PMID: 25363344 Review.
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F. Tarantelli C, et al. Among authors: priebe v. Haematologica. 2019 Jul;104(7):e307-e309. doi: 10.3324/haematol.2018.214759. Epub 2019 Jan 24. Haematologica. 2019. PMID: 30679329 Free PMC article. No abstract available.
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F. Spriano F, et al. Among authors: priebe v. Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182435
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Mensah AA, Spriano F, Sartori G, Priebe V, Cascione L, Gaudio E, Tarantelli C, Civanelli E, Aresu L, Rinaldi A, Damia G, Lovati E, Zucca E, Stathis A, Pietra C, Bertoni F. Mensah AA, et al. Among authors: priebe v. Blood Adv. 2021 May 25;5(10):2467-2480. doi: 10.1182/bloodadvances.2020003566. Blood Adv. 2021. PMID: 33999145 Free PMC article.
ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G, Napoli S, Cascione L, Chung EYL, Priebe V, Arribas AJ, Mensah AA, Dall'Angelo M, Falzarano C, Barnabei L, Forcato M, Rinaldi A, Bicciato S, Thome M, Bertoni F. Sartori G, et al. Among authors: priebe v. J Exp Clin Cancer Res. 2021 Nov 11;40(1):357. doi: 10.1186/s13046-021-02159-3. J Exp Clin Cancer Res. 2021. PMID: 34763718 Free PMC article.
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, Priebe V, Rinaldi A, Golino G, Mensah AA, Aresu L, Zucca E, Pileri S, Witcher M, Brown B, Wahlestedt C, Giles F, Stathis A, Bertoni F. Spriano F, et al. Among authors: priebe v. Blood Adv. 2020 Sep 8;4(17):4124-4135. doi: 10.1182/bloodadvances.2020001879. Blood Adv. 2020. PMID: 32882003 Free PMC article.
12 results